Overexpression of VEGF and VEGFR2 in chronic hepatitis and liver cirrhosis
Journal Title: RESEARCH AND CLINICAL MEDICINE - Year 2016, Vol 0, Issue 1
Abstract
VEGF (vascular endothelial growth factor) and the receptor for VEGF- Flk-1 (fetal liver kinase 1) are important players of normal and pathologic angiogenesis. Also, it was proved that they are involved in tumor progression and metastasis in many tumors types by overexpression in cancer cells. Liver malignances and premalignant lesions represent controversial issues concerning VEGF and VEGFR2 (vascular endothelial growth factor receptor 2) expression and their potential involvement in the progression of inflammatory and cirrhotic lesions and also in malignant transformation is virtually unknown. The aim of this work was to describe the differentiate expression and distribution of VEGF and VEGFR2 in chronic hepatitis and liver cirrhosis, and according to these findings to better characterize the molecular profiling of liver disease with malignant transformation potential. We investigated 20 cases with chronic hepatitis and cirrhosis on specimens taken during surgery. Immunohistochemistry was performed in all cases for VEGF, VEGFR2, and FVIII related antigen (Von Willebrand factor). We found significant correlation between HAI (histological activity index) value, VEGF and VEGFR2 expression and factor FVIII related antigen in central part of specimens with chronic hepatitis. Liver cirrhosis lacks this correlation. Our findings suggested that VEGF dependent angiogenesis is more active in chronic hepatitis in the center of the lesion compared with cirrhosis where MVD (microvessel density) is higher at the periphery of the nodules. We hypothesize that the involvement of VEGF and VEGFR2 complex in development of chronic hepatitis and liver cirrhosis could be considered for the use of anti VEGF antibodies as adjuvant therapy in early stages of these diseases.
Results of peginterferon alpha-2a treatment in patients with chronic hepatitis B in the Western part of Romania
Objective: Currently there are two major types of antiviral therapy in HBV chronic liver disease: PegInterferon alpha-2a and nucleoside/ nucleotide agents. The aim of this study was to evaluate the response to PegInterfe...
Limits of anti-angiogenic therapy
Angiogenesis is controlled by the balance between molecules that have positive and negative regulatory activities and this concept has led to the notion of the angiogenic switch, which depends on an increased production...
Therapeutic potential of angiogenesis inhibitor mixtures in cancer treatment
It is generally understood that improvement of cancer therapies is achieved by the combination of drugs. This approach will improve efficacy, while toxicity and the risk for drug resistance may be decreased. In this revi...
Cerebellum developmental challenges: From morphology to molecular issues
Introduction: It is known that, throughout the development of the nervous system, the cellular migratory routes are an important part of its expansion; therefore, the cerebellum is ‘sprinkled’ with cellular changes durin...
Is there still a place for liver biopsy for the evaluation of chronic liver diseases in the era of non-invasive methods?
Chronic liver diseases are quite frequent in daily medical activity. Chronic viral hepatitis (B or C), alcoholic or non-alcoholic liver diseases (ASH or NASH) are not rarely encountered and the evaluation of such patient...